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Inflammation and outcome in end-stage renal failure: Does patients with end-stage renal disease (ESRD). The an-
female gender constitute a survival advantage? nual mortality rate due to CVD is approximately 10- to
Background. Elevated C-reactive protein (CRP) is a strong 20-fold higher than the general population, even whenpredictor of cardiovascular events and all-cause mortality in
adjusted for age, gender, race and diabetes mellitus [2].end-stage renal disease (ESRD) patients. However, although
sex hormones may influence serum levels of inflammatory pro- Several recent studies have reported that chronic inflam-
teins, gender has not been taken into consideration in previous mation, as defined by elevated C-reactive protein (CRP)
studies of inflammation and outcome in ESRD patients. levels, is a strong independent predictor of all-cause and
Methods. We included 663 (374 males) ESRD patients (59
cardiovascular mortality in ESRD patients [3–6]. Avail-1 year) from three European renal centers (Sweden, Germany
able data suggest that the association between inflam-and Italy) in which CRP levels and outcome data (follow-up
33 1 months) were available. The relation between outcome mation and atherosclerosis is particularly strong in ESRD
and serum levels of the soluble intercellular adhesion molecule patients and CRP has been shown to be an independent
(sICAM-1) was evaluated in 312 of the patients.
predictor of intima media thickness and the number ofResults. The present study shows that elevated CRP is a
atherosclerotic plaques in carotid arteries of dialysis pa-strong predictor of outcome, but whereas no difference in all-
cause mortality was observed between non-inflamed (CRP tients [7]. Furthermore, a strong relationship between
3.4 mg/L) males and females, inflamed males had a signifi- elevated CRP levels and the intima media area has been
cantly (log rank 6.1; P  0.01) higher mortality rate than in- documented in predialysis patients [8].flamed females. A strong positive correlation between CRP
Although inflammation has been shown to predict fu-and sICAM-1 was found in the combined patient material ( 
0.37; P 0.0001) as well as in the male (  0.25; P 0.01) and ture cardiovascular events in both apparently healthy
female (  0.52; P 0.0001) subgroups. The Cox proportional women [9] and men [10], comparative studies are scarce
hazard model showed that whereas both elevated sICAM-1 and the impact of gender on outcome has not been studiedand log CRP predicted outcome in males, neither predicted
systematically in inflamed ESRD patients. In this respectoutcome significantly in females.
it is of interest that recent studies in non-renal patientsConclusions. As inflamed female patients have a better out-
come that inflamed males the present observation suggests that have shown that postmenopausal hormone replacement
sex hormones may have important cardioprotective effects that therapy, such as with estrogen, may modulate the con-
limit the effect of inflammation on vascular injury in female
centrations of CRP and vascular adhesion moleculesESRD patients.
[11]. Vascular adhesion molecules, which are up-regu-
lated by a chronic inflammatory response [12], may serve
as indirect markers for endothelial dysfunction, which
Atherosclerotic cardiovascular disease (CVD), which are considered to be an early event in the atherosclerotic
recently has been regarded as an inflammatory disorder process. Thus, by combining data from three large Euro-
[1], remains the main cause of morbidity and mortality in pean renal centers (Sweden, Germany and Italy), we
sought to determine if inflammation is an equally strong
predictor of all-cause mortality in male and female ESRDKey words: gender and renal disease, cardioprotection, vascular injury,
atherosclerotic cardiovascular disease, C-reactive protein, sICAM-1, patients, respectively.
mortality in kidney disease.
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were evaluated close to the start of, or during, dialysis weight (kg)/height (m)2. Overweight was defined as a
BMI 27.5 kg/m2 [14], whereas a BMI less than 20 kg/m2treatment. They were all part of ongoing prospective
studies and detailed clinical information about the patients was defined as being underweight and 20 to 27.5 kg/m2
was considered to be normal weight.included has been reported recently [3, 8, 13]. The Ethi-
cal Committees of the three University Hospitals ap-
Statistical methodsproved the study protocols and informed consent was
obtained from all patients. In summary, the Swedish Values are presented as mean SEM or medians with
P  0.05 taken to indicate significance. For comparisonspatient material included patients with advanced ESRD
(GFR 7 1 mL/min) studied at a time-point close (34 of continuous data between the three renal centers the
Kruskal-Wallis analysis and the Mann-Whitney U-test6 days) to start of dialysis treatment. Fifty-six patients
in whom high sensitivity CRP levels were not available were used. For comparisons of nominal data between
the three renal centers the Chi-square test was used.were not included in the analysis. Seventy-two hemodial-
ysis (HD) patients were treated by conventional bicar- Correlations were determined with regression (r) or
Spearman rank () analysis, as appropriate. Survivalbonate buffered dialysate using either polyamide, cellu-
lose-acetate or hemophane filters, whereas 88 peritoneal analyses were made with the Kaplan-Meier or the Cox
proportional hazards model and the relative risk of deathdialysis (PD) patients were on a 4 to 5 exchanges per
day schedule with standard dialysis bags. Both the Ger- was calculated.
man and Italian cohorts comprised patients on HD treat-
ment using conventional bicarbonate-buffered dialysate.
RESULTS
The Italian patients represented about 70% of the whole
CRP and its relationship to outcome indialysis population being treated in dialysis centers
males and femaleslinked to a Clinical Research center and to the Academic
Unit. The remaining 30% of the patients were excluded The basal clinical characteristics of the ESRD patients
from the three different European renal centers arebecause of the presence of circulatory congestion or ma-
jor infections (20%), because they were hospitalized for given in Table 1. It is noteworthy that the median CRP
levels did not differ significantly between the centers. Itinter-current illnesses, or for logistic reasons/unwilling-
ness to participate in the study (10%). In the German is likely that different criteria for patient selection may
account for the differences observed in mean age, BMIcohort 23 patients with active illness were excluded from
evaluation. The type of dialysis membranes used in the and prevalence of diabetes mellitus (DM) between the
three centers. Although no significant differences in ageItalian [13] and German centers [3] have previously been
described. In all centers dialysis prescriptions were indi- (59  1 vs. 61  1 years) or prevalence of DM (26 vs.
25%) were observed between 374 males and 289 femalesvidualized to achieve the recommended current ade-
quacy targets. In the combined patient group 258 patients in the combined patient material, the median CRP level
(9.2 vs. 5.2 mg/L) was significantly (P  0.001) higherdied during the observation period. Survival was deter-
mined after a mean follow-up of 33  1 months (range in males. Moreover, the prevalence of patients with ele-
vated CRP (3.4 mg/L) was significantly higher in males0.2 to 76.2 months) and measured from the day of exami-
nation until death or censoring, which was made at the than females (76 vs. 62%; P  0.0001).
Significant positive correlations were observed be-end of the follow-up (December 2001 to January 2002)
or at renal transplantation. We also performed a sub- tween age and log CRP in all patients (r  0.25; P 
0.0001) as well as in the male (r  0.26, P  0.00001)analysis of the 225 Italian and 87 of the Swedish patients,
in whom data on soluble intercellular adhesion molecule and female (r  0.27; P  0.0001) subgroups, as shown
in Figure 1. No difference in mortality rate was observed(sICAM-1) was available. Data on sICAM-1 was not
available in the German patients. between the three centers as shown in Figure 2. A sig-
nificantly higher total mortality rate was observed inDeterminations of CRP were carried out using a nephe-
lometric immunoassay (NA Latex CRP Reagent; Behring males (log-rank 12.8; P  0.001) compared to females.
When the patient material was divided into quartilesInstitute, Marburg, Germany) in Sweden and Germany
and a commercially available kit (Behring, Scoppito, according to CRP levels, a highly significant (log-rank
60.1; P  0.00001) difference in mortality rate was ob-L’Aquila, Italy) in Italy. As the detection limit of CRP
was 3.4 mg/L at the Italian renal center this value was served (Fig. 2). The patient material also was divided
according to the chosen cut-off point for CRP (3.4 mg/L)chosen as the cut-off point in the Swedish and German
cohorts also. The levels of sICAM-1 were determined by and gender. As expected, 284 inflamed males had a sig-
nificantly (log-rank 21.9; P  0.00001) higher mortalitya commercially available enzyme-linked immunosorbent
assay (ELISA) kit and standard (R&D Systems Europe rate than 90 non-inflamed males. Similarly, 179 inflamed
females had a significantly (log-rank 16.6; P  0.00001)Ltd., Abingdon, UK) in both the Swedish and Italian
renal centers. Body mass index (BMI) was calculated as higher mortality rate than 110 non-inflamed females.
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Table 1. Basal clinical data from three European renal centers
Italy Germany Sweden Kruskal-Wallis Chi-square
Number 225 278 160 — —
Age years 601 621 541a P  0.0001 —
Body mass index kg/m2 24.60.3 23.30.3b 24.80.4 P  0.0001 —
Mortality rate/year 13% 15% 13% — NS
Prevalence males 56% 54% 62% — NS
Prevalence diabetes mellitus 16% 29%c 28%d — P  0.001
Median CRP mg/L 7.5 (3.4–197.0) 7.6 (0.2–151.0) 8.0 (0.2–163.0) NS —
Prevalence CRP 3.4 mg/L 66% 74% 67% — NS
NS is not significant.
aP  0.0001 vs. Italy and Germany
bP  0.01 vs. Italy and Sweden
cP  0.001 vs. Italy
dP  0.05 vs. Italy
Fig. 1. Correlations between age and soluble intercellular adhesion molecule (sICAM-1; B ) and log C-reactive protein (CRP; A ) in male and
female end-stage renal disease (ESRD) patients. In A, males, N  374; r  0.26; P  0.0001; females, N  289; r  0.27; P  0.0001. In B, males,
N  181; r  0.11; NS; females, N  131; r  0.32; P  0.0002.
However, the results also showed that, whereas no differ- compared to inflamed females (Fig. 2). The median CRP
level did not differ between inflamed males (12.4 mg/L;ence (log-rank 0.5; NS) in outcome was found between
non-inflamed (CRP 3.4 mg/L) males and females, re- range 3.5 to 197.0 mg/L) and females (13.5 mg/L; range
3.5 to 166.0 mg/L). The Cox proportional hazard modelspectively, a significantly higher total mortality rate (log-
rank 6.1; P  0.01) was observed in inflamed males was used to analyze unadjusted and adjusted relative
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Fig. 2. (A) Survival (log-rank 0.8; not signifi-
cant) by Kaplan-Meier in the three renal cen-
ters. (B ) Survival (log-rank 60.1; P  0.0001)
by Kaplan-Meier in 663 ESRD patients di-
vided into CRP-quartiles. (C ) Survival by
Kaplan-Meier according to gender and the
presence of inflammation (CRP3.4 mg/L) at
the start of follow-up. Whereas no significant
difference (log-rank 0.5) in outcome was ob-
served between non-inflamed males and fe-
male, a significantly higher (log-rank 6.1; P 
0.01) mortality rate was observed in inflamed
males compared to females.
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Table 2. Unadjusted and adjusted relative risk for all-cause mortality in 663 end-stage renal disease patients
Unadjusted relative risk Adjusted relative risk
Variable (95% CI) P value (95% CI)a P value
Age (per year) increase 1.05 (1.04–1.06) 0.0001 — —
Male gender 1.26 (1.11–1.43) 0.001 — —
BMI (per kg/m2 ) increase 0.99 (0.97–1.03) NS — —
CRP mg/L
3.4 1 1
3.5–7.6 1.49 (1.20–1.85) 0.001 1.37 (1.10–1.71) 0.01
7.7–16.5 1.82 (1.49–2.22) 0.0001 1.67 (1.36–2.06) 0.0001
16.5 2.00 (1.07–2.05) 0.0001 1.72 (1.40–2.13) 0.0001
a Adjusted for age, body mass index (BMI), renal center and gender
No influence of BMI on mortality
The mean BMI for the whole patient group was 24.1
0.2 kg/m2. No difference in BMI was observed between
males (24.2  0.2 kg/m2) and females (24.1  0.3 kg/m2).
The prevalence of underweight (BMI 20 kg/m2) was
16.6% whereas 19.8% of the patients were considered
overweight (BMI 27 kg/m2). Two hundred fifty-eight
non-survivors had a similar BMI at start of follow-up
(24.1  0.3 kg/m2) compared to 405 survivors (24.1 
0.2 kg/m2). Similarly, a Kaplan-Meier survival analysis
showed no difference in survival (log-rank 0.3) compar-
ing normal weight, underweight and overweight ESRD
patients. No significant correlation was observed be-
tween BMI and CRP (  0.07) in the whole patient
group.
sICAM-1 and its relation to age and outcome
No significant difference (log-rank 1.2) in outcome was
observed comparing 312 patients in which sICAM-1 was
Fig. 3. Receiver operating characteristics (ROC) curve for C-reactive available to 351 patients in which it was not. Moreover,
protein as a predictor of death. Data for CRP values 3.4 mg/L were no significant difference in sICAM-1 level was found
based on 438 patients (Swedish and German cohorts) whereas data on
between males (284  7 ng/mL; N  181) and femalesthe other cut-off points for were based on 663 patients.
(274  6 ng/mL; N  131). A significant (P  0.01)
difference in sICAM-1 levels was observed between
Swedish (254  9 ng/mL) and Italian (290  6 ng/mL)
risk of mortality according to CRP-quartiles, following patients. A strong positive correlation between CRP and
correction for the impact of age, BMI, renal center and sICAM-1 was found in the combined patient material
gender (Table 2). The results showed a stepwise increase (  0.37; P  0.0001) as well as in males (  0.25; P 
in both unadjusted and adjusted relative risk for mortal- 0.01) and females (  0.52; P  0.0001). Significant
ity with increasing CRP levels. Moreover, in another correlations were found between age and sICAM-1 lev-
Cox proportional hazard model analyzing CRP as a con- els in all patients (r  0.17; P  0.01) and in females
tinuous variable (log CRP) a strong independent associa- (r  0.32; P  0.001), whereas no correlation was found
tion between log CRP (OR 2.40; 95% CI 1.88 to 3.07; between age and sICAM-1 levels in males (r  0.11), as
P  0.00001) and outcome was found independently shown in Figure 1. Also, whereas significant positive
of age, BMI and renal center. The receiver operating correlations were observed between age and sICAM-1
characteristics (ROC) curve for CRP as a predictor of in both Swedish (r  0.46; P  0.01) and Italian (r 
death is shown in Figure 3. The area under the ROC 0.27; P  0.01) females no significant correlations were
curve was 0.696, standard error 0.020, 95% confidence observed between age and sICAM-1 in either Swedish
interval 0.656 to 0.736. The cut-off point at which sensi- (R  0.001) or Italian (R  0.08) men. In a stepwise
tivity and specificity were equal (65%) was at a CRP multiple regression model including age, log CRP and
gender, only log CRP (P  0.00001) was significantlylevel of 9 mg/L.
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associated to sICAM-1 levels. No significant difference rather than the dialysis procedure per se, are the main
cause of chronic inflammation in ESRD patients [16].in sICAM-1 levels (276  14 vs. 289  8 ng/mL) were
observed between 65 males aged50 and 116 males50 Indeed, Schindler et al have demonstrated that whereas
optimized HD therapy using ultrapure dialysate andyears of age, respectively. On the other hand, 39 females
50 years of age had significantly lower serum levels of biocompatible dialyzer membranes was able to reduce
elevated CRP levels in HD patients it did not normalizesICAM-1 (237 10 vs. 289 7 ng/mL; P 0.0001) than
92 women aged 50 years. it [17].
The Cox proportional hazard model was used to adjust
Estrogen may modulate the effects of inflammation onsurvival for age, diabetes mellitus, log CRP, gender, and
vascular injurysICAM-1 in the whole patient group as well as in the
male (N  181) and female (N  131) subgroups. The An important and novel finding of the present study
is that whereas survival does not differ between non-results showed that besides age (OR 1.05; 95% CI 1.03
to 1.07; P  0.0001), male gender (OR 1.38; 95% CI inflamed male and female ESRD patients, the influence
of inflammation on survival was more pronounced in1.13 to 1.69; P  0.01) and diabetes mellitus (OR 1.33;
95% CI 1.06 to 1.63; P  0.05) both elevated sICAM-1 males than females. Thus, it could be speculated that
female sex hormones, such as estrogen, may influence the(OR 1.003; 95% CI 1.001 to 1.005; P  0.01) and log
CRP (OR 1.87; 95% CI 1.24 to 2.84; P  0.01) levels inflammation-induced vascular injury. Several potential
mechanisms by which estrogen may be able to modulatepredicted poor outcome in the whole patient group. Sub-
sequent subgroup analysis with regard to gender showed the atherosclerotic process have been suggested in the
literature. As inflammation has been shown to increasethat besides age (OR 1.04; 95% CI 1.03 to 1.07; P 
0.0001), both elevated sICAM-1 (OR 1.003; 95% CI oxidative stress [18], it is of interest that unlike most
steroid hormones, estrogen has been shown to possess1.001 to 1.005; P  0.05) and log CRP (OR 2.17; 95%
CI 1.30 to 3.54; P 0.001) levels predicted poor outcome significant antioxidant properties [19]. Although the mech-
anism(s) by which an inflammatory reaction may causein males, whereas diabetes mellitus did not (OR 1.25;
95% CI 0.93 to 1.64). In females, on the other hand, accelerated atherosclerosis are not well understood, one
key in the development of atherosclerosis is the adhesiononly age (OR 1.06; 95% CI 1.03 to 1.10; P  0.0001)
predicted poor outcome significantly whereas log CRP of leukocytes to the vascular endothelium, a process
mediated by vascular adhesion molecules, such as sI-(OR 1.26; 95% CI 0.56 to 2.72), sICAM (OR 1.005; 95%
CI 1.000 to 1.010; P  0.08) and diabetes mellitus (OR CAM-1 [20]. Elevated levels of pro-inflammatory cyto-
kines, which is a common phenomenon in ESRD patients1.39; 95% CI 0.97 to 1.96) did not.
[21], can up-regulate the expression of adhesion mole-
cules from endothelial cells [12]. Thus, it has been sug-
DISCUSSION
gested that an inflammatory response may be a major
Inflammation is a common feature and predicts cause of endothelial dysfunction in ESRD patients [22].
outcome in ESRD In this respect it is of interest that endothelial function
is abnormal in postmenopausal women [23] and thatIn the present study, 70% of all patients had CRP
levels 3.4 mg/L whereas 45% of all patients had CRP estrogen replacement therapy reverses endothelial dys-
function in postmenopausal women, especially if theylevels 10 mg/L, which confirms that ESRD may be
considered a chronic inflammatory state [15]. Also, in are hypertensive [24]. In the present study we demon-
strated a significant positive correlation between age andagreement with a previous observation by Yeun et al
[4], our combined analysis shows that elevated CRP is sICAM-1 in female ESRD patients only (Fig. 1). Thus,
as lower levels of sICAM-1 were found in younger pre-strongly associated with poor outcome in ESRD patients
independently of both age and gender (Fig. 2). Predicting menopausal women it could be suggested that estrogen
exerts its cardioprotective effects is by limiting the in-survival in ESRD patients is important. In previous stud-
ies different cut-off points for CRP (8 to 15 mg/L) were flammatory response to injury by modulating the expres-
sion of cellular adhesion molecules from the endotheliumchosen to show that elevated CRP predicts outcome [3,
5, 6]. The results from the present study, using receiver [25]. However, it should be pointed out that the direction
and strength of the association with hormone replace-operating characteristics (ROC), shows that by using a
cut-off point of 10 mg/L a sensitivity of about 60% (true ment therapy use with inflammation markers seems to
differ depending on the protein analyzed. Thus, whereaspositive values) is achieved whereas 30% are false posi-
tive (1-specificity; Fig. 3). It is of interest that the median postmenopausal hormone therapy significantly increases
CRP levels, they also might be considered anti-inflam-CRP level did not differ between the three dialysis cen-
ters, indicating that yet undialyzed ESRD patients have matory as they reduce the concentration of adhesion
molecules, such as sICAM-1 [26] and E-selectin [11].CRP levels similar to ESRD patients on HD. This sup-
port the hypothesis that factors associated with ESRD, Taken together, further studies are needed to investigate
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whether postmenopausal hormone replacement therapy insufficient number of included patients. Finally, it must
confers cardiovascular risk reduction through an in- be emphasized that the majority of women in the present
flammation-sensitive mechanism. study were post-menopausal and serum levels of sex
hormones were not assessed. Thus, further prospective
Does overweight constitute a survival advantage in studies are needed to investigate the possible impact of
European ESRD patients? postmenopausal hormones, such as estrogen, on endo-
In the present study of European patients no differ- thelial function during chronic inflammation in post-
ence in survival was observed when comparing over- menopausal females with ESRD.
weight (BMI 27.5 kg/m2), normal weight and under-
Conclusionweight (BMI 20 kg/m2) ESRD patients. Our findings
differ from those recently presented by Fleishmann et The present study, combining three large cohorts of
al, who demonstrated that excess body weight was associ- patients from different parts of Europe, indicates a sig-
ated with a survival advantage in a predominantly black nificantly better outcome for inflamed female than male
American HD patient population [27]. There may be ESRD patients. Indirectly, our results could suggest that
several reasons for the discrepant findings reported. sex hormones might have important cardioprotective ef-
First, whereas the majority of our patients were of Cauca- fects that limit the effect inflammation might have on
sian origin, 89% of the patients in the study by Fleish- progressive vascular injury in ESRD patients. As re-
mann et al were of African American race [27]. Second, search on the impact of gender on the prevalence of
whereas only about 20% of our patients were considered malnutrition, inflammation and atherosclerosis, until re-
overweight almost 40% of all patients in the American cently [28], has been a neglected area in nephrology, we
study had a BMI27.5 kg/m2. Finally, it must be appreci- propose that gender is an important factor that needs to
ated that the present study may not have included a be taken into consideration in future outcome studies.
sufficient number of patients to disclose significant differ-
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